biotech.today

Details

  • ●Modalities: multispecific antibodies
  • ●Therapeutic areas: immunology, dermatology, oncology
  • ●Key targets: IL-4Rα, IL-31, TNFα, IL-17A, IL-17F
  • ●Indications: atopic dermatitis, inflammatory bowel disease, psoriasis, solid tumors
  • ●Funding: CHF 180M+

Partners & investors

  • BioMedPartners· Investor
  • HBM Partners· Investor
  • Novo Holdings· Investor
  • Gilde Healthcare· Investor

Key considerations

  • ●AI tools in use: MATCH multispecific antibody platform
  • ●Computational antibody engineering
  • ●J&J acquired NM26 program
  • ●Kaken Pharmaceutical licensing deal (NM81, Nov 2025)

Pipeline

  • Preclinical2
  • Phase 11
Get live updates on Numab Therapeutics’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

David Urech

CEO

antibody engineeringbiotech leadershipimmunology
Visit website →LinkedIn →